免疫缀合物是将抗体与主要针对肿瘤细胞的不同药剂（例如毒素、药物、放射性核素或细胞因子）相结合的有前途的分子。然而，肿瘤微环境（TME）由指导肿瘤生长和进展的各种细胞和分子线索组成的复杂网络组成，仍然是有效癌症治疗的主要挑战。我们的综述强调了 TME 在免疫偶联物癌症治疗中的关键作用，研究了与 TME 复杂的相互作用以及 TME 靶向免疫偶联物的最新进展。我们探索针对 TME 成分的策略，利用多种抗体，如中和抗体、免疫调节抗体、免疫检查点抑制剂、免疫刺激抗体和双特异性抗体。此外，我们还讨论了不同的免疫偶联物，阐明它们的作用机制、优点、局限性以及在癌症免疫治疗中的应用。此外，我们还重点介绍了增强免疫偶联物安全性和有效性的新兴技术，例如抗体工程、联合疗法和纳米技术。最后，我们总结了 TME 靶向免疫偶联物的当前进展、观点和未来发展。版权所有 © 2024 Elsevier B.V。保留所有权利。

Immunoconjugates are promising molecules combining antibodies with different agents, such as toxins, drugs, radionuclides, or cytokines that primarily aim to target tumor cells. However, tumor microenvironment (TME), which comprises a complex network of various cells and molecular cues guiding tumor growth and progression, remains a major challenge for effective cancer therapy. Our review underscores the pivotal role of TME in cancer therapy with immunoconjugates, examining the intricate interactions with TME and recent advancements in TME-targeted immunoconjugates. We explore strategies for targeting TME components, utilizing diverse antibodies such as neutralizing, immunomodulatory, immune checkpoint inhibitors, immunostimulatory, and bispecific antibodies. Additionally, we discuss different immunoconjugates, elucidating their mechanisms of action, advantages, limitations, and applications in cancer immunotherapy. Furthermore, we highlight emerging technologies enhancing the safety and efficacy of immunoconjugates, such as antibody engineering, combination therapies, and nanotechnology. Finally, we summarize current advancements, perspectives, and future developments of TME-targeted immunoconjugates.Copyright © 2024 Elsevier B.V. All rights reserved.